Researchers hope that antisense oligo clinical trial failures in Huntington’s will shed light on mechanism and drug biodistribution and galvanize ongoing drug development efforts.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Change history
21 June 2021
A Correction to this paper has been published: https://doi.org/10.1038/s41587-021-00987-4
26 July 2021
A Correction to this paper has been published: https://doi.org/10.1038/s41587-021-01017-z
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Sheridan, C. Questions swirl around failures of disease-modifying Huntington’s drugs. Nat Biotechnol 39, 650–652 (2021). https://doi.org/10.1038/s41587-021-00955-y
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41587-021-00955-y
